Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Panel study

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    536 result(s) found for: Panel study. Displaying page 1 of 27.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-002678-19 Sponsor Protocol Number: SP148MP201 Start Date*: 2018-03-20
    Sponsor Name:SmartPractice
    Full Title: Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study
    Medical condition: Metal induced contact dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003842-34 Sponsor Protocol Number: MK-5592-127 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formul...
    Medical condition: Invasive Fungal Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) Outside EU/EEA BE (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005459-18 Sponsor Protocol Number: SP122PM2201 Start Date*: 2015-09-10
    Sponsor Name:SMARTPRACTICE
    Full Title: Clinical Evaluation of Metal Panel Allergens Mercury, Aluminum and Palladium Dose Response Study
    Medical condition: Diagnosis of Allergic Contact Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004579-22 Sponsor Protocol Number: GAM-25 Start Date*: 2008-10-14
    Sponsor Name:Octapharma AG
    Full Title: A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam ...
    Medical condition: Subjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002042-36 Sponsor Protocol Number: CNTO148UCO2001 Start Date*: 2014-07-10
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Phase 2a Open-label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) CZ (Completed) BG (Completed) PL (Completed) DE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000168-18 Sponsor Protocol Number: Mekos 07 7P3.2 301 Start Date*: 2008-04-10
    Sponsor Name:Allerderm
    Full Title: Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol
    Medical condition: Diagnosis of Allergic Contact Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010790 Contact dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002113-19 Sponsor Protocol Number: 42756493CAN2002 Start Date*: 2019-10-31
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations
    Medical condition: Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) DE (Trial now transitioned) ES (Ongoing) BE (Completed) IT (Completed) Outside EU/EEA SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011182-86 Sponsor Protocol Number: BLX883-204 Start Date*: 2009-07-24
    Sponsor Name:Biolex Therapeutics, Inc
    Full Title: 480 Study: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects with HCV Genotype 1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron™ Plus Ribavirin ...
    Medical condition: Approximately 72 subjects with chronic hepatitis C (treatment naive, genotype 1) will be included in a 12 week open label randomized trial with 2 panels (approximately 40 subjects in PANEL A and ap...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005602-10 Sponsor Protocol Number: 1.1 Start Date*: 2022-01-20
    Sponsor Name:Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB)
    Full Title: POESIA Study: Pleiotropic effects of PCSK 9 inhibition and bempedoic acid - Changes in Platelet Function and Inflammation Markers
    Medical condition: platelet activity and inflammation markers in patients with coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001443-49 Sponsor Protocol Number: MK0524A-158 Start Date*: 2012-11-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents with Heterozygous Familial Hypercholesterolemia
    Medical condition: Heterozygous Familial Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10058108 Dyslipidaemia PT
    14.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    14.1 100000004850 10057099 Heterozygous familial hypercholesterolaemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000137-19 Sponsor Protocol Number: Start Date*: 2007-08-07
    Sponsor Name:Leiden University Medical Center
    Full Title: Metyrapone as additive treatment in patients with major depression
    Medical condition: unipolar depressive episode without psychotic features according to DSM-IV-TR
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027515 Metyrapone challenge test LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003070-31 Sponsor Protocol Number: VAN00002 Start Date*: 2022-01-24
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants
    Medical condition: Invasive Meningococcal Disease (IMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10076061 Meningococcal immunisation PT
    Population Age: Infants and toddlers, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2004-004899-36 Sponsor Protocol Number: Mekos 05 P379/1 Start Date*: 2005-02-23
    Sponsor Name:Mekos Laboratories
    Full Title: Clinical evaluation of the 3 allergens: Methyldibromoglutharonitrile, Parthenolide and Goldsodiumthiosulphate for "TRUE Test Panel 3" - a phase II, dose-response study.
    Medical condition: Diagnosis of Allergic Contact Dermatitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023095-31 Sponsor Protocol Number: HUM-001 Start Date*: 2012-11-28
    Sponsor Name:Humedics GmbH
    Full Title:
    Medical condition: liver resection
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10024689 Liver function analyses HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005391-29 Sponsor Protocol Number: 2021/2014 Start Date*: Information not available in EudraCT
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of mannitol on delayed graft function after cadaveric renal transplantation
    Medical condition: Kidney transplantation
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000070-11 Sponsor Protocol Number: MK-6072-001 Start Date*: 2017-12-11
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK 6072, Human Monoclonal An...
    Medical condition: Prevention of recurrent Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10012748 Diarrhoea, Clostridium difficile LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) PT (Completed) SE (Prematurely Ended) DE (Completed) NO (Completed) HU (Completed) PL (Completed) Outside EU/EEA GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-001563-29 Sponsor Protocol Number: V72P4 Start Date*: 2007-09-25
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Singl...
    Medical condition: no medical, condition; healthy, at risk volunteers will be recruited for a clinical trial to receive three vaccinations against meningococcal strain B and one vaccination against meningococcal stra...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004734-25 Sponsor Protocol Number: V72P3 Start Date*: 2014-11-11
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine OMV When Administered at an 0-2-6-Month Schedul...
    Medical condition: Prophylaxis Aganist Invasive Meningococcal Disease
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001522-84 Sponsor Protocol Number: V72P6 Start Date*: 2006-08-29
    Sponsor Name:Novartis Vaccines and Diagnostics Srl.
    Full Title: A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, when Administered to Health...
    Medical condition: The Novartis Meningococcal B recombinant vaccine is intended for prevention of meningitis and/or septicemia caused by Neisseria meningitidis serogroup B. The objective of the Novartis Meningococcal...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-001241-20 Sponsor Protocol Number: 747-214 Start Date*: 2022-11-23
    Sponsor Name:INTERCEPT PHARMACEUTICALS INC.
    Full Title: A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination with Obeticholic Acid in S...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 09:16:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA